Loading
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Previous close
$1.35
−$0.02 · -1.46%
Regular session · ET · Market data may be delayed.
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Day range
Current $1.35
52-week range
Current $1.35
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
81
Deep Value
Sentiment
50
Mixed
Risk
47
Elevated Risk
Momentum
54
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Day range
Current $1.35
52-week range
Current $1.35
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 183.88M USD | 76.99M USD | 237K USD | 596K USD | 1.39M USD |
| Cost of goods sold | 4.75M USD | 1.26M USD | — | — | — |
| Gross profit | 179.14M USD | 75.74M USD | 237K USD | 596K USD | 1.39M USD |
| Research and development | 73.72M USD | 103.74M USD | 125.05M USD | 95.52M USD | 85.73M USD |
| Selling, general, and administrative | 159.26M USD | 145.73M USD | 69.14M USD | 43.63M USD | 29.67M USD |
| Operating expenses | 232.97M USD | 249.47M USD | 194.18M USD | 139.15M USD | 115.39M USD |
| Interest income | 18.12M USD | 19.61M USD | 18.15M USD | 2.53M USD | 527K USD |
| Interest expense | 32.66M USD | 18.5M USD | 8.31M USD | 6.88M USD | 3.74M USD |
| Depreciation and amortization | 1.2M USD | 1.22M USD | 1.03M USD | 868K USD | 783K USD |
| Operating income | −53.84M USD | −173.73M USD | −193.94M USD | −138.55M USD | −114M USD |
| Net income | −85.78M USD | −174.57M USD | −184.13M USD | −141.9M USD | −116.11M USD |
Company facts updated Sep 13, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$5.89
336.30% upsideFunds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI30.74M0.29%10.57B USD0.35%$156.2-0.40%
Vanguard Morningstar Total Stock Market ETFVTI26.38M0.00%2.3T USD0.03%$376.31+0.82%
iShares Russell 2000 ETFIWM19.78M0.03%77.55B USD0.19%$288.89+0.41%
Vanguard Extended Market ETFVXF7.97M0.01%93.7B USD0.05%$237.76+0.68%
iShares Russell 2000 Growth ETFIWO7.33M0.05%14.32B USD0.24%$367.63+0.54%
iShares Biotechnology ETFIBB6.68M0.06%10.3B USD0.44%$202.93+0.14%
Vanguard Russell 2000 ETFVTWO4.05M0.02%17.4B USD0.06%$116.76+0.36%
Schwab U.S. Small-Cap ETFSCHA3.6M0.02%22.43B USD0.03%$33.79+0.42%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
